SalaryGuide
AboutPricingFor Employers

Marketing jobs

3 marketing jobs

Haemonetics Interventional Technologies logo
1 day ago

Manager, Product Marketing

Haemonetics Interventional Technologies

California, MO (Remote)Full time$104K/yr – $176K/yr
Haemonetics Interventional Technologies logo
1 day ago

Manager, Product Marketing

Haemonetics Interventional Technologies

Chicago, IL (On-site)Full time$104K/yr – $176K/yr
Haemonetics Interventional Technologies logo
4 months ago

VP of Global Marketing, Interventional Technologies

Haemonetics Interventional Technologies

Middlesex County, MA (Remote)Full time$210K/yr – $357K/yr

All marketing roles in the US

Get alerts for this search

All marketing roles in the US

Get alerts for this search

3 jobs
Haemonetics Interventional Technologies logo

Manager, Product Marketing

Haemonetics Interventional Technologies

California, MO (Remote)

$104K/yr - $176K/yrIn-houseFull-timeManager4+ years exp.
1 day ago
Haemonetics Interventional Technologies logo

Manager, Product Marketing

Haemonetics Interventional Technologies

Chicago, IL (On-site)

$104K/yr - $176K/yrIn-houseFull-timeManager4+ years exp.
1 day ago
Haemonetics Interventional Technologies logo

VP of Global Marketing, Interventional Technologies

Haemonetics Interventional Technologies

Middlesex County, MA (Remote)

$210K/yr - $357K/yrIn-houseFull-timeSenior level10+ years exp.
4 months ago
Haemonetics Interventional Technologies logo
Haemonetics Interventional Technologies

Manager, Product Marketing

California, MO (Remote)

$104K/yr – $176K/yrManager4+ years expFull time

Posted 1 day ago

Top 1% of applicants do these two things.

The other 99% submit and hope. You're about to do something different.

Job Summary

Own downstream marketing for the IVT franchise, including launch planning, cross-functional partnership, and regional messaging, while translating clinical data into field-ready content and ensuring commercial readiness.

  • Lead downstream marketing and content strategy for IVT
  • Coordinate launches and cross-functional programs
  • Translate clinical evidence into compelling messaging

Job Description

Responsibilities

  • Own downstream marketing strategy and commercial content for the IVT franchise, ensuring alignment with upstream product management, clinical marketing, and commercial priorities across regions.
  • Create and execute differentiated promotional and educational content and programs for the IVT franchise, optimizing channel mix across sales tools, events, and paid and owned media.
  • Drive launch planning and execution for IVT product label expansions and new indications, from brief through Agile review to full field deployment.
  • Conduct market analysis and competitive intelligence for the venous closure segment, generating insights to inform IVT strategy and messaging.
  • Monitor IVT product performance and gather field and customer feedback, partnering with Product Management on product improvements while ensuring regulatory compliance.
  • Own conference content strategy and product demo approach for IVT in partnership with Marketing Communications.
  • Lead voice of sales program for IVT, capturing structured field feedback on content gaps, competitive dynamics, and unmet commercial needs; translate insights into actionable marketing improvements.
  • Partner closely with Product Management to ensure commercial readiness at every stage of the IVT product lifecycle, translating clinical evidence, product specifications, and market insights into compelling downstream messaging and field-ready content.
  • Partner with international commercial and marketing teams to adapt IVT core content and messaging for regional market requirements and support regional go-to-market execution.
  • Maintain effective relations with both internal and external customers.

Requirements

  • Bachelor's Degree B.S.
  • 4+ years Product marketing or downstream marketing experience in medical device
  • Demonstrated track record of leading product launches in a regulated environment, including content development and Agile/MLR review processes
  • Prior people management experience with a record of developing high-performing marketing talent
  • Experience marketing interventional cardiology, vascular, or structural heart products
  • Strong commercial storytelling skills; ability to translate complex clinical data into crisp, field-ready messaging
  • Proficiency in launch planning and cross-functional program management
  • Experience building and managing agency relationships and marketing budgets
  • Competitive intelligence development and sales enablement content creation
  • Strong executive communication and presentation skills

Preferred

  • Experience marketing interventional cardiology, vascular, or structural heart products

Benefits

  • In addition to compensation, the Company offers a competitive suite of benefits to its employees, including without limitation, a 401(k) with up to a 6% employer match and no vesting period, an employee stock purchase plan, “flexible time off” for salaried employees and, for hourly employees, accrual of three to five weeks’ vacation annually (based on tenure), accrual of up to 64 hours (annually) of paid sick time, paid and/or floating holidays, parental leave, short- and long-term disability insurance, tuition reimbursement, and/or health and welfare benefits.
Haemonetics Interventional Technologies logo

Haemonetics Interventional Technologies

2.6 Glassdoor

A successful case requires everything working together without disruption. When you have the right tools, you can focus on the procedure you planned. Haemonetics Interventional Technologies is a growing portfolio of procedure-enabling solutions that are thoughtfully designed and elegantly simple to help you achieve the desired outcomes more efficiently.

Founded in 2002
Boston, Massachusetts, USA
241 employees (5 in marketing)
hospital.haemonetics.com
43% recommend to a friend
58% CEO approval

Traffic Signals

Monthly Visitors
40.5K
Monthly Google Ads Budget
$29
Traffic Source Mix
Search
43.1%
Direct
43.7%
Referral
8%
Social
3.2%
Paid
1.9%

Headcount Trend

Current headcount: ~241

Marketing Team

Marketing Team Size
5 (2% of company)
Median Career Experience
17 years
Median Tenure
4.8 years
Marketing Roles Posted (Last 30 Days)
1

People

Marketing Leadership

Joseph Gray
Joseph Gray
Global Marketing Manager
At the company for 1 year 3 months
Kris McCulloch
Kris McCulloch
Senior Marketing Manager, Electrophysiology
At the company for 6 years

Funding

Total Funding
$181.2M
Last Raise
$45M
Series Unknown, 6 years ago

Funding History

  • Jul 2020
    Series Unknown • $45M
  • Feb 2018
    Debt Financing • $11M
  • Mar 2017
    Series Unknown • $30M

Recent News

5 Insightful Analyst Questions From Haemonetics’s Q3 Earnings Call
Nov 12, 2025 • Yahoo Finance
Haemonetics raises 2026 guidance, projects 7%–10% organic growth ex CSL amid strong plasma and hospital performance
Nov 8, 2025 • MSN
HAE Q3 Deep Dive: Margin Expansion and Portfolio Rationalization Drive Outperformance
Nov 7, 2025 • The Globe and Mail
Haemonetics Is Still Undervalued, Even After The Rally (NYSE:HAE)
Nov 7, 2025 • Seeking Alpha
Earnings call transcript: Haemonetics beats Q2 2026 estimates, stock surges By Investing.com
Nov 7, 2025 • Investing.com UK
Haemonetics reports Q2 adjusted EPS $1.27, consensus $1.11
Nov 6, 2025 • TipRanks
Haemonetics Corporation Q2 Fiscal 2026 Results
Nov 6, 2025 • TradingView
Earnings call transcript: Haemonetics beats Q2 2026 estimates, stock surges By Investing.com
Nov 6, 2025 • Investing.com UK
Haemonetics Corp (HAE) Q2 2026 Earnings Call Highlights: Strong
Nov 6, 2025 • GuruFocus
Haemonetics (HAE): Evaluating Valuation After Earnings Beat and Ongoing Competitive Pressures
Nov 5, 2025 • simplywall.st
How Recent Developments Are Shaping the Haemonetics Investment Story
Oct 28, 2025 • Yahoo Finance
Haemonetics (HAE): Exploring Valuation Following Recent Share Price Decline
Oct 21, 2025 • simplywall.st
Haemonetics stock hits 52-week low at 50.62 USD
Sep 16, 2025 • Investing.com
The Top 5 Analyst Questions From Haemonetics’s Q2 Earnings Call
Aug 13, 2025 • Yahoo Finance
Haemonetics Corporation (NYSE:HAE) Q1 2026 Earnings Call Transcript
Aug 12, 2025 • MSN
HAE Q2 Deep Dive: Margin Expansion Amid Revenue Decline and Product Execution Challenges
Aug 11, 2025 • Yahoo Finance
I’m Recommending Haemonetics Again, But With Caveats (Ratings Upgrade) (NYSE:HAE)
Aug 11, 2025 • Seeking Alpha
Haemonetics stock rating downgraded by Raymond James on vascular closure slowdown
Aug 11, 2025 • Investing.com
Earnings call transcript: Haemonetics beats Q1 2026 earnings, stock drops
Aug 7, 2025 • Investing.com
Baird initiates Haemonetics stock with outperform rating on market position
Jun 25, 2025 • Investing.com
Haemonetics at Goldman Sachs Conference: Strategic Growth and Challenges
Jun 9, 2025 • Investing.com
HAEMONETICS CORP SEC 10-K Report
May 21, 2025 • TradingView
JMP maintains Haemonetics stock $100 target post-results
May 20, 2025 • Investing.com
Arteriotomy Closure Devices Market Size, Future Trends and ...
Jan 4, 2024 • Artrocker
Vascular Closure Systems Market Size, Share, Scope, and ...
Dec 20, 2023 • Artrocker
Haemonetics revenue hits record high amid global expansion ...
Sep 22, 2023 • The Business Journals
Apparatus and Methods for Delivering Hemostatic Materials for Blood Vessel …
Aug 3, 2023 • Google Patent
Apparatus and Methods for Accessing and Closing Multiple Penetrations on a …
Jul 10, 2023 • Google Patent
Catheter with sealed hydratable hemostatic occlusion element
Jun 6, 2023 • Google Patent
Vascular closure devices and methods providing hemostatic enhancement
Jul 15, 2022 • Google Patent
Haemonetics to buy bloodstopper medtech Cardiva Medical in $510M deal
Jan 20, 2021 • FierceBiotech
Cardiva Medical wins FDA PMA for Vascade MVP vascular closure device
— • Mass Device
Medical device maker Cardiva Medical files for a $75 million IPO
— • Renaissance Capital
Cardiva Medical wins FDA PMA for Vascade MVP vascular closure device
— • Mass Device
Haemonetics to acquire Cardiva
— • Mass Device
FDA approves Cardiva’s new bioabsorbable vessel closure system
— • Fierce Biotech
Cardiva Medical adds $11m for vascular closure devices
— • Mass Device
Cardiva Medical® Announces FDA Approval of VASCADE® Vascular Closure System for Use in Femoral Vein Closure
— • Bio Portfolio